Sweden's Ascelia Pharma Q4 operating loss narrows to SEK 15.8 mln

Reuters

Feb 05

Sweden's Ascelia Pharma Q4 operating loss narrows to SEK 15.8 mln

Overview

Swedish biotech firm's Q4 operating loss narrows to SEK 15.8 mln
Earnings per share for Q4 improved to SEK -0.13 from SEK -0.29
FDA accepted Orviglance NDA, decision expected by July 2026

Outlook

Company expects FDA decision on Orviglance by 3 July 2026
Ascelia Pharma has cash runway into Q4 2026
Company sees strong strategic interest from potential partners

Result Drivers

FDA ACCEPTANCE - FDA accepted Orviglance NDA for review, aiming for decision by July 2026, marking a critical step in drug development
CASH RUNWAY - Directed share issue in September 2025 raised SEK 30 mln, extending cash runway into Q4 2026
PARTNERSHIP PROGRESS - Ongoing partnering discussions gained momentum with regulatory timeline established for Orviglance

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 EPS		-SEK 0.13
Q4 Cash Flow From Operations		-SEK 21.70 mln
Q4 EBIT		-SEK 15.80 mln

Analyst Coverage

Wall Street's median 12-month price target for Ascelia Pharma AB is SEK8.00, about 207.7% above its February 4 closing price of SEK2.60

Press Release: ID:nMFN9m34lD

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2609323122"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2609323122\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2609323122?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 14:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609323122","market":"us","top_or_hot":-1,"title":"Sweden's Ascelia Pharma Q4 operating loss narrows to SEK 15.8 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Sweden's Ascelia Pharma Q4 operating loss narrows to SEK 15.8 mln </title></head><body><p><span>Overview</span></p><ul><li><p>Swedish biotech firm's Q4 operating loss narrows to SEK 15.8 mln</p></li><li><p>Earnings per share for Q4 improved to SEK -0.13 from SEK -0.29</p></li><li><p>FDA accepted Orviglance NDA, decision expected by July 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects FDA decision on Orviglance by 3 July 2026</p></li><li><p>Ascelia Pharma has cash runway into Q4 2026</p></li><li><p>Company sees strong strategic interest from potential partners</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>FDA ACCEPTANCE - FDA accepted Orviglance NDA for review, aiming for decision by July 2026, marking a critical step in drug development</p></li><li><p>CASH RUNWAY - Directed share issue in September 2025 raised SEK 30 mln, extending cash runway into Q4 2026</p></li><li><p>PARTNERSHIP PROGRESS - Ongoing partnering discussions gained momentum with regulatory timeline established for Orviglance</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-SEK 0.13</p></td><td></td></tr><tr><td><p>Q4 Cash Flow From Operations</p></td><td></td><td><p>-SEK 21.70 mln</p></td><td></td></tr><tr><td><p>Q4 EBIT</p></td><td></td><td><p>-SEK 15.80 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>Wall Street's median 12-month price target for Ascelia Pharma AB is SEK8.00, about 207.7% above its February 4 closing price of SEK2.60</p></li></ul><p>Press Release: <span>ID:nMFN9m34lD</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sweden's Ascelia Pharma Q4 operating loss narrows to SEK 15.8 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSweden's Ascelia Pharma Q4 operating loss narrows to SEK 15.8 mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-05 14:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Sweden's Ascelia Pharma Q4 operating loss narrows to SEK 15.8 mln </title></head><body><p><span>Overview</span></p><ul><li><p>Swedish biotech firm's Q4 operating loss narrows to SEK 15.8 mln</p></li><li><p>Earnings per share for Q4 improved to SEK -0.13 from SEK -0.29</p></li><li><p>FDA accepted Orviglance NDA, decision expected by July 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects FDA decision on Orviglance by 3 July 2026</p></li><li><p>Ascelia Pharma has cash runway into Q4 2026</p></li><li><p>Company sees strong strategic interest from potential partners</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>FDA ACCEPTANCE - FDA accepted Orviglance NDA for review, aiming for decision by July 2026, marking a critical step in drug development</p></li><li><p>CASH RUNWAY - Directed share issue in September 2025 raised SEK 30 mln, extending cash runway into Q4 2026</p></li><li><p>PARTNERSHIP PROGRESS - Ongoing partnering discussions gained momentum with regulatory timeline established for Orviglance</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-SEK 0.13</p></td><td></td></tr><tr><td><p>Q4 Cash Flow From Operations</p></td><td></td><td><p>-SEK 21.70 mln</p></td><td></td></tr><tr><td><p>Q4 EBIT</p></td><td></td><td><p>-SEK 15.80 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>Wall Street's median 12-month price target for Ascelia Pharma AB is SEK8.00, about 207.7% above its February 4 closing price of SEK2.60</p></li></ul><p>Press Release: <span>ID:nMFN9m34lD</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01049","symbol_name":"时富投资","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nL1N3Z1092:1","article_id":"2609323122","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609323122","pubTimestamp":1770273611,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sweden's Ascelia Pharma Q4 operating loss narrows to SEK 15.8 mlnOverviewSwedish biotech firm's Q4 operating loss narrows to SEK 15.8 mlnEarnings per share for Q4 improved to SEK -0.13 from SEK -0.29F","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01049":"时富投资","BK1201":"家庭装饰零售"},"translate_title":"瑞典Ascelia Pharma第四季度运营亏损收窄至1580万瑞典克朗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01049":0.9},"content_text":"Sweden's Ascelia Pharma Q4 operating loss narrows to SEK 15.8 mln OverviewSwedish biotech firm's Q4 operating loss narrows to SEK 15.8 mlnEarnings per share for Q4 improved to SEK -0.13 from SEK -0.29FDA accepted Orviglance NDA, decision expected by July 2026OutlookCompany expects FDA decision on Orviglance by 3 July 2026Ascelia Pharma has cash runway into Q4 2026Company sees strong strategic interest from potential partnersResult DriversFDA ACCEPTANCE - FDA accepted Orviglance NDA for review, aiming for decision by July 2026, marking a critical step in drug developmentCASH RUNWAY - Directed share issue in September 2025 raised SEK 30 mln, extending cash runway into Q4 2026PARTNERSHIP PROGRESS - Ongoing partnering discussions gained momentum with regulatory timeline established for OrviglanceKey DetailsMetricBeat/MissActualConsensus EstimateQ4 EPS-SEK 0.13Q4 Cash Flow From Operations-SEK 21.70 mlnQ4 EBIT-SEK 15.80 mlnAnalyst CoverageWall Street's median 12-month price target for Ascelia Pharma AB is SEK8.00, about 207.7% above its February 4 closing price of SEK2.60Press Release: ID:nMFN9m34lDFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}